VION 2.5
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
Vion Pharmaceuticals, Inc., a development stage company, develops therapeutics and technologies for the treatment of cancer. The company’s products in clinical development stage are Triapine, which would be used for the prevention of the replication of tumor cells; and CLORETAZINE, which would be used as an agent in acute myeloid leukemia and myelodysplastic syndromes. Its products in the preclinical development stage are Heterocyclic Hydrazones, KS119, and TAPET. The Heterocyclic Hydrazones are anticancer compounds that have demonstrated potent anti-tumor effects in preclinical studies. The KS119, an additional cytotoxic compound from the sulfonyl hydrazine class, has been demonstrated in preclinical studies to be selective for hypoxic cells, which are found in tumors. The Triapine, a drug delivery system using modified salmonella bacteria, is designed to deliver anticancer agents directly to solid tumors.
TRAD 9.8
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
TradeStation Group, Inc., through its subsidiary, TradeStation Securities, Inc., offers the TradeStation platform for the active trader and certain institutional trader markets. The TradeStation platform provides direct-access order execution, as well as enables clients to design, test, monitor, and automate their custom trading strategies. This online brokerage service covers equities, equities options, futures, and forex transactions. In addition, the company offers subscription services through another subsidiary, TradeStation Technologies, Inc. The subscription services include strategy trading features and functions, real-time charts and quotes, news, analytical charting, and all other features included in the TradeStation platform other than trade order placement and other trading or brokerage-related features or services. TradeStation Technologies also owns and operates the TradeStationWorld.com strategy trading and development community.
THRX 18.0
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
Theravance, Inc. engages in the discovery, development, and commercialization of small molecule medicines for respiratory disease, bacterial infections, overactive bladder, and gastrointestinal disorders. As of April 7, 2005, telavancin, the company’s injectable antibiotic, was in Phase 3 clinical studies for the treatment of Gram-positive infections and in patients whose infections were due to methicillin-resistant Staphylococcus aureus in both complicated skin and skin structure infections and hospital-acquired pneumonia. Its other product candidates in development include TD-6301 for overactive bladder; TD-2749 and TD-5108 for gastrointestinal motility dysfunction; and TD-4756 for emergence from hypnosis. Theravance has various other product candidates in the identification and preclinical testing stages. The company has a collaboration agreement with GlaxoSmithKline (GSK) to develop and commercialize long acting beta2 agonist product candidates for the treatment of asthma and chronic obstructive pulmonary disease.
IAO .24
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
A Global, Inc., through its subsidiaries, provides media, entertainment, and technology products and services. The company, through QuikCAT.com, Inc., developed an Internet acceleration product, iNet, using video, picture, and audio compression algorithms. It markets this technology in Australia and New Zealand. The company, through Rex Tokyo, Ltd., supplies automatic medal dispensing machines, automatic cigarette butt disposal systems, lighting systems and Pachinko balls, and other Pachinko accessory products, as well as new Pachinko slot machines to the Pachinko and slot machine gaming industry in Japan. IA Global, through Fan Club Entertainment, Ltd., provides advertising, merchandising, publishing, Web site, and data management services in Japan.
RTK 1.4 .. percentage change of institutional shares held in the latest qtr as compared to prior qtr = +25
stockcharts.com[w,a]daclyiay[pc40!c200!f][vc60][iut!La12,26,9!Ll14]&pref=G
Rentech, Inc. engages in marketing and licensing a patented and proprietary gas-to-liquids process for conversion of synthesis gas made from natural gas, industrial off-gas, or solid or liquid carbon-bearing materials, including coal, into fuels and chemicals. The company operates in four segments: Alternative Fuels, Paints, Oil and Gas Field Services, and Industrial Automation systems. The Alternative Fuels segment engages in development, owning, and licensing a proprietary technology to energy industry. The company’s Paints segment manufactures and markets water-based stains, sealers, and coatings. Its Oil and Gas Field Services segment provides well logging services to the oil and gas industry. The Industrial Automation Systems segment manufactures microprocessor controlled industrial automation systems primarily for the fluid power industry. The principal products produced from the company’s process include diesel fuel, naphtha, fuel for fuel cells, and waxes that can be further processed into specialty products, such as synthetic lubricants, base oils, and drilling fluids. |
